|
DK2155788T3
(da)
*
|
2007-04-03 |
2012-10-08 |
Amgen Res Munich Gmbh |
Krydsartsspecifikke bispecifikke bindemidler
|
|
RU2769948C2
(ru)
*
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
WO2008119567A2
(en)
*
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
AU2008234019B2
(en)
*
|
2007-04-03 |
2014-05-29 |
Amgen Research (Munich) Gmbh |
Cross-species-specific bispecific binders
|
|
US20110014117A1
(en)
*
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
WO2009009406A1
(en)
*
|
2007-07-06 |
2009-01-15 |
Smithkline Beecham Corporation |
Antibody formulations
|
|
US20110091447A1
(en)
*
|
2008-03-13 |
2011-04-21 |
The Hospital For Sick Children |
Lymphocyte control of obesity and insulin resistance
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
RU2547600C2
(ru)
*
|
2008-10-01 |
2015-04-10 |
Эмджен Рисерч (Мьюник) Гмбх |
Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
|
|
EP3106468A1
(en)
|
2008-10-01 |
2016-12-21 |
Amgen Research (Munich) GmbH |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
|
WO2010132872A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Novimmune S.A |
Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
|
|
WO2011050106A2
(en)
*
|
2009-10-20 |
2011-04-28 |
Tolerx, Inc. |
Anti-cd3 antibody dosing in autoimmune disease
|
|
BR112012022223B1
(pt)
|
2010-03-01 |
2022-08-09 |
Cytodyn Inc |
Formulação de proteína concentrada, uso e método de preparação da mesma
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
WO2012098238A1
(en)
|
2011-01-21 |
2012-07-26 |
Novimmune S.A. |
Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
|
|
US8974782B2
(en)
*
|
2011-02-07 |
2015-03-10 |
Glaxo Group Limited |
Treatment of stroke comprising anti-MAG antibodies
|
|
CN103619876A
(zh)
|
2011-03-10 |
2014-03-05 |
Hco抗体股份有限公司 |
双特异性三链抗体样分子
|
|
CN107827985A
(zh)
|
2011-05-21 |
2018-03-23 |
宏观基因有限公司 |
能够与人和非人cd3结合的cd3结合分子
|
|
WO2013073968A2
(en)
*
|
2011-09-12 |
2013-05-23 |
Industrial Research Limited |
Agents for modulation of cell signalling
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
HRP20181717T1
(hr)
|
2012-09-27 |
2018-12-28 |
Merus N.V. |
Bispecifična igg protutijela kao aktivatori t stanice
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
TW201501724A
(zh)
*
|
2013-03-15 |
2015-01-16 |
Glaxosmithkline Ip No 2 Ltd |
低濃度抗體調配物
|
|
PL3587448T3
(pl)
*
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2994490A1
(en)
*
|
2013-05-10 |
2016-03-16 |
Numab AG |
Bispecific constructs and their use in the treatment of various diseases
|
|
DK3406633T3
(da)
|
2013-07-25 |
2022-03-28 |
Cytomx Therapeutics Inc |
Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
|
|
KR102497443B1
(ko)
|
2014-03-28 |
2023-02-08 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
WO2016077451A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
ES2693596T3
(es)
|
2015-07-10 |
2018-12-12 |
Merus N.V. |
Anticuerpo que se une a CD3 humano
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
WO2017223111A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
|
ES2986900T3
(es)
*
|
2016-08-29 |
2024-11-13 |
Tiziana Life Sciences Plc |
Formulaciones de anticuerpos anti-cd3
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
HRP20240767T1
(hr)
|
2016-09-14 |
2024-09-13 |
Teneoone, Inc. |
Cd3 vezujuća antitijela
|
|
PE20240950A1
(es)
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
CA3046489A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
BR112019012354A2
(pt)
|
2016-12-21 |
2019-11-26 |
Teneobio, Inc. |
anticorpos apenas de cadeia pesada anti-bcma
|
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
WO2018213467A1
(en)
|
2017-05-16 |
2018-11-22 |
The Johns Hopkins University |
Manabodies and methods of using
|
|
JP7247113B2
(ja)
*
|
2017-06-06 |
2023-03-28 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
ミクログリアの活性化を抑制する方法
|
|
MX2019015563A
(es)
|
2017-06-20 |
2020-07-28 |
Teneoone Inc |
Anticuerpos anti-bcma unicamente de cadena pesada.
|
|
CN110891971B
(zh)
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019033051A1
(en)
|
2017-08-11 |
2019-02-14 |
City Of Hope |
RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR)
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
WO2019133761A1
(en)
|
2017-12-27 |
2019-07-04 |
Teneobio, Inc. |
Cd3-delta/epsilon heterodimer specific antibodies
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
MX2021003765A
(es)
|
2018-10-03 |
2021-07-15 |
Xencor Inc |
Proteínas il-12 de fusión a fc heterodimérico.
|
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
US20210340273A1
(en)
|
2018-10-11 |
2021-11-04 |
Inhlbrx, inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020076977A2
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
EP3864049A1
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
JP7467438B2
(ja)
|
2018-10-18 |
2024-04-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｒｓｖ抗体の製剤及びその使用方法
|
|
CN113015748B
(zh)
|
2018-10-31 |
2025-12-12 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
CN116726361A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
KR20210096640A
(ko)
*
|
2018-11-29 |
2021-08-05 |
하버 바이오메드 테라푸틱스 리미티드 |
항-pd-l1 항체 제제
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
AU2020252556B2
(en)
|
2019-04-05 |
2026-02-05 |
Teneobio, Inc. |
Heavy chain antibodies binding to PSMA
|
|
IL288024B2
(en)
|
2019-05-14 |
2025-12-01 |
Provention Bio Inc |
Methods and compositions for preventing type
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
EP3998081A4
(en)
|
2019-07-05 |
2023-07-12 |
Ono Pharmaceutical Co., Ltd. |
TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
|
|
JP7725466B2
(ja)
|
2019-11-13 |
2025-08-19 |
アムニクス ファーマシューティカルズ， インコーポレイテッド |
バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
|
|
WO2021119482A1
(en)
|
2019-12-13 |
2021-06-17 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
MX2022013453A
(es)
|
2020-04-29 |
2022-11-16 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
|
|
CA3176436A1
(en)
|
2020-05-08 |
2021-11-11 |
Tahamtan Ahmadi |
Bispecific antibodies against cd3 and cd20
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
CA3182372A1
(en)
|
2020-06-25 |
2021-12-30 |
Amunix Pharmaceuticals, Inc. |
Her-2 targeted bispecific compositions and methods for making and using the same
|
|
JP7773528B2
(ja)
|
2020-08-19 |
2025-11-19 |
ゼンコア インコーポレイテッド |
抗ｃｄ２８組成物
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
EP4323404A1
(en)
*
|
2021-04-16 |
2024-02-21 |
Tiziana Life Sciences PLC |
Subcutaneous administration of antibodies for the treatment of disease
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
JP2026505405A
(ja)
|
2023-02-10 |
2026-02-13 |
アムニクス ファーマシューティカルズ， インコーポレイテッド |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法
|
|
US20240400696A1
(en)
|
2023-04-17 |
2024-12-05 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting epidermal growth factor receptor and methods for making and using the same
|
|
KR20250019203A
(ko)
|
2023-07-31 |
2025-02-10 |
한국과학기술원 |
종양 침투 t세포의 종양 내 다클론성 증식을 통한 재조합 면역세포 기반 암 치료용 세포 치료제
|
|
WO2025193146A1
(en)
|
2024-03-13 |
2025-09-18 |
Berg Thoren Fredrik |
Trail receptor binding molecules
|
|
WO2025199352A2
(en)
|
2024-03-20 |
2025-09-25 |
Juno Therapeutics, Inc. |
Antibodies specific for solute carrier family 34 member 2 (slc34a2)
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2026024863A2
(en)
|
2024-07-24 |
2026-01-29 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
|